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Abstract
Infection with genotype 4 of the Hepatitis C virus is common in Africa and the Mediterranean area,
but has also been found at increasing frequencies in injection drug users in Europe and North America.
Full length viral sequences to characterize viral diversity and structure have recently become
available mostly for subtype 4a, and studies in Egypt and Saudi Arabia, where high proportions of
subtype 4a infected patients exist, have begun to establish optimized treatment regimens. However
knowledge about other subtype variants of genotype 4 present in less developed African states is
lacking. In this study the full coding region from so far poorly characterized variants of HCV genotype
4 was amplified and sequenced using a long range PCR technique. Sequences were analyzed with
respect to phylogenetic relationship, possible recombination and prominent sequence characteristics
compared to other known HCV strains. We present for the first time two full-length sequences from
the HCV genotype 4k, in addition to five strains from HCV genotypes 4d and 4f. Reference sequences
for accurate HCV genotyping are required for optimized treatment, and a better knowledge of the
global viral sequence diversity is needed to guide vaccines or new drugs effective in the world wide
epidemic.
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Introduction
Hepatitis C virus (HCV) infection is a global health problem with 170 million infected people
worldwide [Lauer and Walker, 2001]. Hepatitis C virus is a member of the Hepacivirus genus
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in the Flaviviridae family. Current classifications distinguish between 6 major genotypes and
multiple subtypes [Simmonds et al., 2005], and very recently a novel seventh genotype has
been described [Murphy et al., 2007a]. These HCV genotypes differ in their genetic structure,
clinical features, and their geographical distribution. Genotype 1b is observed worldwide,
whereas genotypes 1a and 3a are regionally concentrated in European and North American
countries, genotype 2 in the Mediterranean region, far east and Western Africa, genotype 5 in
South Africa, genotype 6 in South East Asia [Simmonds et al., 2005], and genotype 7 was
found in patients from the Democratic Republic of Congo [Murphy et al., 2007a]. Genotype 4
is encountered throughout Africa and Mediterranean countries, but more recently has spread
to Europe and North America mostly by immigrants and injection drug users [Nguyen and
Keeffe, 2005]. Significant frequencies of genotype 4 infections have also been reported in India
and the Caribbean [Nguyen and Keeffe, 2005].
Accurate diagnosis of HCV genotypes is clinically relevant as genotypes differ in their response
rates to the current standard treatment with pegylated Interferon alpha and Ribavirin. Clinical
trials indicate sustained virological response rates of up to 80% in patients infected with
genotype 2 and 3 after 24 weeks of therapy, considerably higher than the 42–52% achieved
with a 48 week treatment duration in genotype 1 infection [Fried et al., 2002; Hadziyannis et
al., 2004; Manns et al., 2001]. While there remains a paucity of controlled studies for genotypes
5 and 6 which are therefore often treated similar to genotype 1, recent data indicate that
genotype 4 infected patients may achieve viral clearance in 60–80% of cases [Alfaleh et al.,
2004; El-Zayadi et al., 2005; Hasan et al., 2004]. Aside from drug response rates, knowledge
regarding worldwide patterns of viral sequence diversity is also essential for research efforts
to design efficient vaccines and new drugs to fight the global epidemic.
In order to provide a systematic structure to capture the global viral diversity a recent consensus
conference delineated guidelines for the nomenclature of HCV variants, including a list of
reference sequences to enable accurate classification of diagnostic samples and potential new
strains [Simmonds et al., 2005]. Major genotypes were defined as strains that form
phylogenetically distinct clusters and differ from other genotype sequences by 31% – 33% on
the nucleotide level, compared to only 20% – 25% differences between subtypes. Up to 19
subtypes were assigned for each of the 6 major genotypes, however only a provisional
classification was possible for many of these since only sub-genomic sequences (e.g. from
NS5B or the Core/E1 region) are available for many presumed subtypes. Although in most
cases the sub-genomic sequences provide sufficient information for clinical purposes, the
recent discovery of inter-genotypic recombinants [Colina et al., 2004; Kalinina et al., 2004;
Kalinina et al., 2002; Legrand-Abravanel et al., 2007; Noppornpanth et al., 2006] has
highlighted the need for full length sequences to fully define novel viral genotypes and
subtypes.
In an effort towards assisting in the definitive classification of all currently provisionally
assigned subtypes this study presents five viral sequences confirming the classification of
strains 4d and 4f, and for the first time characterizes two sequences covering the full open
reading frame (ORF) of the HCV subtype 4k.
Methods
Genotyping
Viral RNA was extracted from 140µl of plasma using the Qiagen vRNA Extraction Kit Qiagen,
Hilden, Germany). Primers HCV_Geno_F and HCV4_Geno_R (Supplementary Table 1) were
used for reverse transcription and subsequent amplification of a 1kb sequence fragment in
NS5B in a single RT-PCR reaction using the Qiagen One-Step RT-PCR kit with 3µl of vRNA
as template. PCR conditions on an MJ PTC-200 thermal cycler (BioRad) were reverse
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transcription at 50°C for 60 min., denaturation at 95°C for 15 min., followed by 50 PCR
amplification cycles with 94°C for 30 s, 62°C for 30 s and 72°C for 90 s, and a final extension
at 68°C for 20 min. PCR products were sequenced bidirectionally on an ABI 3130x automated
sequencer (Applied Biosystems, Foster City, CA, USA). Sequences were then compared by
phylogenetic analysis to published reference sequences.
Strategy for PCR amplification of the full HCV open reading frame
First, three PCR fragments in addition to the genotyping fragment were amplified (Figure 1).
Fragment 1 covered the 5’UTR, while fragment 2 covered the region between the genotyping
fragment and the 3’end of the coding sequence. Fragment 3 amplified a small sequence island
in NS3. Primer sequences are given in Supplementary Table1. PCR conditions were as
described in the genotyping reaction above, with annealing temperatures of 58°C or 62°C.
Together with the genotyping fragment sequencing of these PCR products provided small
sequence islands that enabled the design of strain specific primers for the subsequent
amplification of hemi-genome fragments which together covered the entire HCV ORF.
cDNA for the amplification of hemi-genome fragments was synthesized using Superscript III
Reverse Transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions
with 5µl of viral RNA and 1µl of 2µM strain-specific reverse primer. Hemi-genomes were
amplified in a two round nested PCR using the Expand Long Range dNTPack (Roche Applied
Science, Indianapolis, IN, USA) with 1µl DMSO and 0.6µl of each 25µM strain specific primer
(Supplementary Table 1) in a 50µl reaction volume. PCR conditions were 94°C for 2 min, 50
cycles of denaturation at 94°C for 20 sec, annealing at 58°C for 30 sec and extension at 68°C
for 3.5 min, followed by a final extension at 68°C for 7 min. After the first 10 cycles, the
extension time was increased by 15 sec after each cycle. For optimal results in the first round
PCR it was necessary to slow down the ramping times between the denaturation and annealing
step starting with 1°C/sec from 94°C to 63°C, then 0.3°C/sec to 60°C and 0.2°C/sec to 58°C.
Where necessary the results could be further improved by separating the primers from the
enzyme by PCR wax during PCR setup. The size of the amplicons was checked by gel
electrophoresis, and sequences were obtained by sequence walking using strain specific
primers.
Generation of clonal sequences
A small region of E2 was cloned from viral RNA of patient EU392169 to evaluate a possible
mixed infection suspected based on chromatograms from bulk sequences. Using primers
DAV9905_F and DAV9905_R1 or DAV9905_R2 (Supplementary Table 1) two PCR
fragments 393 and 695 base pairs in size were amplified in a 50 cycle one-step RT-PCR as
described above. PCR fragments were cloned using the Topo TA cloning kit for sequencing
(Invitrogen, Carlsbad, CA, USA) according to the manufacturers instructions. Plasmids from
16 clones were extracted using the DirectPrep 96 Miniprep Kit (Qiagen, Hilden, Germany),
and were sequenced bidirectionally using M13 primers.
Sequence analysis
Sequence chromatograms were aligned and edited using Sequencher (Gene Codes Corp., Ann
Arbor, MI, USA). Nucleotide and amino acid sequences from different strains were aligned
using ClustalX [Thompson et al., 1997] and Se-Al v2.0a11 (http://evolve.zoo.ox.ac.uk)
software, and phylogenetic trees were constructed by the neighbor-joining method with Jukes-
Cantor corrected distances on PAUP4.0b10 software (Sinauer, Sunderland, MA, USA).
Bootstrap values are based on 1,000 replications. Pairwise nucleotide distances between
sequences were calculated using Mega 4.0 [Tamura et al., 2007]. Simplot [Lole et al., 1999]
was used to evaluate possible recombinations between different viral strains.
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Results and Discussion
Study subjects
Seven discarded plasma samples were received from clinical diagnostic laboratories in Great
Britain and Cameroon. Approval to conduct these investigations for all patient samples
included in the study was obtained from the institutional review board at Massachusetts General
Hospital. Viral sequences from the Core and NS5B region of samples CM9905 and CM1578
originating from patients in Cameroon (new Genbank accession numbers EU392169 and
EU392170) have been previously published [Ndjomou et al., 2003]. No demographic or
clinical patient information was available for the other five samples that were obtained as
discarded samples after HCV genotyping from diagnostic laboratories in Great Britain. Each
of these samples were previously typed as either unspecified genotypes 4 other than 4a, or as
the uncommon HCV genotypes 4d, 4f and 4k according to results based on restriction fragment
length polymorphisms (RFLP) in the 5’UTR [Davidson et al., 1995] or sequence analysis in
the Core/E1 or NS5B regions [Mellor et al., 1995; Viazov et al., 1997].
Provisional identification of HCV subtypes
The highly conserved 5’UTR allows reliable and sensitive PCR amplification for determination
of viral loads, and sequences from this genomic region are therefore widely used also for HCV
genotyping. However, due to the low degree of sequence diversity in the 5’UTR as compared
to the more informative Core/E1 and NS5B regions, assays based on the 5’UTR are limited in
their ability to distinguish some major genotypes and to differentiate many HCV subtypes
[Chinchai et al., 2003; Mellor et al., 1996; Murphy et al., 2007b; Stuyver et al., 1996].
To confirm the previously determined HCV genotypes and establish provisional subtype
classifications for these samples part of the NS5B region was therefore amplified and
sequenced. Sequences were then compared by phylogenetic analysis to published reference
sequences of all major genotypes, and of confirmed [Chamberlain et al., 1997; Franco et al.,
2007; Timm et al., 2007] or provisionally assigned [Simmonds et al., 2005] HCV genotype 4
subtypes that are available from the Los Alamos National Laboratory (LANL) database
(http://hcv.lanl.gov, NCBI accession numbers provided in figure 2). Clustering of the new
sequences with subtype specific reference sequences suggested classification of these samples
as HCV subtypes 4d, 4f and 4k (Figure 2).
Definitive assignment of HCV subtypes based on sequences covering the entire HCV open
reading frame
In order to characterize further the world wide sequence diversity, confirm provisionally
assigned subtype classifications, and provide a set of reference sequences for each viral
subtype, the entire HCV ORF and part of the 5’- and 3’UTRs from 7 samples of the putative
genotypes 4d, 4f and 4k were amplified and sequenced, comprising between 9269 and 9303
nucleotides in length. Sequences are available from GenBank under accession numbers
EU392169 - EU392175.
To confirm the provisional classification based on NS5B sequence, the novel strains were
aligned to selected full length sequences of the major HCV genotypes and to all full length
sequences of genotype 4 subtypes currently available at public databases. As expected, a
phylogenetic analysis revealed that five of the novel viral strains clustered together with
published sequences of subtypes 4d and 4f, whereas the sequences provisionally assigned to
subtype 4k formed a separate cluster within genotype 4, but distinct from other existing
genotype 4 strains. All clusters were supported by high bootstrap values (Figure 3).
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HCV genotypes typically differ by around 30% in their nucleotide sequence, compared to 20%–
25% differences between subtypes [Simmonds et al., 2005]. To verify that the novel HCV
strains, especially the genotype 4k strains, represented an independent genotype 4 subtype,
pairwise genetic distances were calculated between these and the full length HCV sequences
included in Figure 3. Genotype 4 sequences clustering together in Figure 3 showed between
6.8% (5.1%) and 9.0% (5.6%) pairwise nucleotide (amino acid) distances, whereas sequences
from separate clusters differed by 19.5% – 21.7% (11.9% – 14.5%). In addition, all genotype
4 sequences exhibited 28.6% – 34.2% (20.8% – 28.8%) pairwise nucleotide (amino acid)
distances from all other genotypes. Taken together these data confirm subtypes 4d and 4f and
additionally establish the subtype 4k as an independent viral subtype within genotype 4 based
on full ORF sequences according to consensus criteria [Simmonds et al., 2005].
Recombinations between viral strains of different genotypes and subtypes have been described
in patients from Russia, Peru, France and Vietnam [Colina et al., 2004; Kalinina et al., 2004;
Kalinina et al., 2002; Legrand-Abravanel et al., 2007; Noppornpanth et al., 2006]. In order to
examine the new sequences for inter-genotypic sequence recombination each sequence was
compared to all other nucleotide sequences included in Figure 3. Percent similarities between
sequences were calculated in a sliding window of 200 residues shifted in 20 nucleotide steps
across the genome using Simplot software. No evidence for recombination was found (Figure
4).
Prominent sequence characteristics in comparison with other HCV genotypes and subtypes
Prominent characteristics were examined that distinguish these new sequences from other HCV
genotypes and subtypes. Amino acid positions are reported relative to the genotype 1a strain
H77 (NCBI accession number A009606) with lower case letters indicating insertions relative
to this reference strain according to published guidelines [Kuiken et al., 2006].
Compared to other genotype 4 sequences several alterations in the envelope genes were
observed in some of these new sequences, namely a single amino acid deletion in position 479a
in all genotype 4d sequences, and a two amino acid insertion in position 575 and 576 in all
genotype 4f sequences. Notably, in the latter position in patient EU392169 unclear patterns in
bulk sequence chromatograms indicated a possible mixed infection of viral quasispecies with
and without this insertion. Indeed the presence of two quasispecies populations differing by a
two amino acid insertion and an adjacent single amino acid substitution was confirmed in clonal
sequences (Figure 5). Otherwise the two populations were highly similar to each other within
the cloned area, but differed from sequences of other patients infected with genotype 4f by
several amino acids (data not shown). Thus, the two amino acid insertion in patient EU392169
appeared to represent a polymorphism between viral quasispecies, but not a superinfection
with two different viral strains.
Moreover, in NS5A deletion of one (genotype 4d & 4k) or two (genotype 4f) amino acids was
found in position 2263a and 2264 (Figure 6). Of note, genotype 4k sequences differed from
all other genotype 4 sequences by a four amino acid insertion in position 2235–2238 that was
identical to genotype 1 and 3 sequences (Figure 6). Last, there was a single amino acid insertion
in all genotype 4f sequences at position 2331a in NS5A. Together with the >23% pairwise
amino acid distances between genotypes these data illustrate considerable structural and
potential functional differences between viral genotypes and subtypes.
HCV sequence variation is not only relevant for epidemiological or evolutionary studies, but
also has important clinical implications as HCV genotypes differ considerably in their
susceptibility to pegylated Interferon-α and Ribavirin [Fried et al., 2002; Hadziyannis et al.,
2004; Manns et al., 2001]. Sequence differences in a 40 amino acid region in NS5A (termed
the “Interferon Sensitivity Determining Region”, ISDR) in genotype 1 infected patients have
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been associated with treatment response rates in several Asian studies [Enomoto et al., 1996;
Hung et al., 2003; Watanabe et al., 2001]. However many studies have failed to confirm this
observation in European or North American populations [Airoldi et al., 2004; Chung et al.,
1999; Halfon et al., 2000; Pascu et al., 2004; Squadrito et al., 1997; Squadrito et al., 1999;
Squadrito et al., 2002; Veillon et al., 2004]. Therefore, although the clinical significance of
ISDR mutations remains unclear, it is striking that considerable differences between genotypes
with accumulation of insertions and deletions are seen within or in close proximity to the ISDR.
While these differences thus far appeared to be genotype-specific, a novel aspect highlighted
by this study is that considerable changes may also be observed between subtypes, as shown
here in Figure 6 within genotype 4 for subtype 4k sequences. Only a handful of controlled
studies to explore optimal treatment conditions are currently available for genotype 4 [Alfaleh
et al., 2004; El-Zayadi et al., 2005; Hasan et al., 2004], however none of these have included
a subtype analysis. Therefore it will be important to evaluate whether treatment results are
generally applicable to the entire spectrum of HCV subtypes especially in areas with larger
sequence diversity such as Africa or South East Asia.
Summary
Viral sequence diversity of HCV strains present in Europe and the United States is well
characterized and established treatment regimens for the locally common variants of genotypes
1, 2 and 3 are intensively studied and optimized. In contrast, viral strains that predominate in
less developed regions such as Africa or South East Asia remain poorly defined. This study
presents a set of full length reference sequences of genotypes 4d and 4f, and provides the first
two full length sequences for genotype 4k. These data will enable more accurate genotyping
and subtyping approaches and provide a basis for in depth studies of treatment options suitable
for these genotypes. More extensive studies are needed to characterize the global sequence
diversity as a basis for drug design and worldwide vaccination efforts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Strategy for PCR amplification of the entire HCV open reading frame. A genotyping fragment
in NS5B and two additional fragments 1 and 3 provide small sequence islands that enable
generation of strain specific primers for the amplification of large hemi-genome fragments.
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Figure 2.
Neighbour joining tree based on partial NS5B sequences (nucleotide positions 7939–8269
relative to the HCV genotype 1a reference sequence H77) of HCV strains presented in this
manuscript (shaded in grey), and sequences provisionally assigned as HCV subtype 4
references [Simmonds et al., 2005]. The numbers of bootstrap replicates supporting relevant
nodes (total 1000 replicates) are indicated. Clusters of novel and reference nucleotide
sequences suggest classification of the new strains as HCV subtypes 4d, 4f and 4k.
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Figure 3.
Neighbour joining tree based on published nucleotide sequences covering the full HCV open
reading frame, with novel full-length sequences shaded in grey. The numbers of bootstrap
replicates supporting relevant nodes (total 1000 replicates) are indicated. Full-length sequences
provisionally assigned to subtypes 4d, 4f and 4k form distinct clusters within genotype 4
separate from other published subtypes, thus confirming their definition as separate subtypes
according to consensus criteria [Simmonds et al., 2005]. HCV genotypes, subtypes and NCBI
reference numbers are given for each sequence.
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Figure 4.
Simplot graph displaying pairwise nucleotide similarities between the test sequence
4k.EU392171 and full length sequences of all sequences included in Figure 3. Pairwise
similarities are plotted based on calculations from a 200 nucleotide window sliding in 20
nucleotide steps across the genome. As illustrated, only the sequence of the second genotype
4k patient EU392173 shows consistently higher nucleotide similarities with 4k.EU392171
compared to all other sequences, with no evidence for recombination between this genotype
4k sequence and any other HCV genotype.
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Figure 5.
Amino acid alignment of clonal sequences from patient EU392169 documenting a mixed
infection with two different viral quasispecies with and without a two amino acid insertion in
position 575 and 576.
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Figure 6.
Amino acid alignment of reference sequences and novel strains in the NS5A region, including
the Interferon Sensitivity Determining Region (ISDR, shaded in grey). Novel strains and
noticeable parts of the sequences are marked in grey. Dashes indicate gaps or deletions. Amino
acid positions are indicated relative to the HCV genotype 1a reference sequence H77.
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